All In Biotech

Drug Trial Radar · NCT07895238

A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC

An Open-Label, Randomized Controlled Clinical Trial of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,088 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,088

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Dec 31, 2032

Study completion Dec 31, 2034

Sponsor

Lead sponsor
West China HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, multicenter, phase III clinical study to compare the efficacy and safety of perioperative treatment with adebrelimab plus platinum-based chemotherapy versus adebrelimab adjuvant therapy in patients with resectable stage II-IIIB non-small-cell lung cancer(NSCLC).

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Adebrelimab (SHR-1316) + chemotherapyDrug

    3 cycles of adebrelimab 1200 mg plus platinum-containing doublet chemotherapy administered every 3 weeks (Q3W); followed by postoperative adjuvant adebrelimab 1200 mg

  • AdebrelimabDrug

    Patients who have undergone curative-intent surgery receive adjuvant chemotherapy, followed by adebrelimab 1200 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EFSTime frame: Approximately 96 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.